By Siddhi Mahatole and Kunal Das Nov 18 (Reuters) – The US Food and Drug Administration has approved Regeneron Pharmaceuticals’ drug to treat adults with generalized myasthenia gravis, a rare autoimmune disease, the company said on Wednesday. The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor […]
Health
US FDA approves Regeneron’s drug for generalized myasthenia gravis
Audio By Carbonatix
By Siddhi Mahatole and Kunal Das
Nov 18 (Reuters) – The US Food and Drug Administration has approved Regeneron Pharmaceuticals’ drug to treat adults with generalized myasthenia gravis, a rare autoimmune disease, the company said on Wednesday.
The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the most common form of the disease.
Generalized myasthenia gravis causes muscle weakness that can affect movement, speech, swallowing, and breathing.
Livsayis is administered by injection under the skin once every three months, the longest dosing interval among FDA-approved treatments for generalized myasthenia gravis, Regeneron said.
The approval was based on a late-stage study in which patients receiving Livsayis improved by 4.5 points on a measure of daily activities after 24 weeks, compared with a 2.2-point improvement for those receiving a placebo.
Livsayis is the first approved small interfering RNA (siRNA) therapy for the condition and Regeneron’s first approved medicine in both the siRNA and neurology fields, the drugmaker said.
The approval gives Regeneron an entry into a growing market for generalized myasthenia gravis treatments. Existing therapies include AstraZeneca’s Soliris and Ultomiris, Argenx’s Vyvgart and Vyvgart Hytrulo, and UCB’s Rystiggo and Zilbrysq.
Unlike those treatments, Livsayis is the first treatment for generalized myasthenia gravis that uses RNA-silencing technology to reduce production of a protein involved in the disease.
RBC Capital Markets analyst Brian Abrahams said Livsayis is not central to Regeneron’s investment case, with investors likely looking for additional pipeline wins or acquisitions with clearer multibillion-dollar revenue potential to drive the stock higher.
The drug carries a boxed warning for serious meningococcal infections and is available only through a restricted safety program consistent with other FDA-approved medicines that reduce C5 activity.
Patients must be vaccinated against meningococcal bacteria before starting treatment.
The drug is also under review in the European Union, with a decision expected in the second half of 2027.
(Reporting by Siddhi Mahatole and Kunal Das in Bengaluru; Editing by Shinjini Ganguli and Rashmi Aich)

